Last checked at 24 Jan 2020 16:31
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, Maryland - 24 January 2020: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences company, announces that on 20 January 2020, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). The annual 2020 grants were approved at a Board Meeting in December 2019, subject to issuance being following announcement of the Company's recent trading update ("Trading Update"). Details of the Option Grants are given below:
Option Grants to PDMRs | |
Doerfler, Doug | 390,200 |
Holtz, Ron | 177,600 |
Thompson, J. Stark | 26,900 |
Mandell, Art | 26,900 |
Erck, Stan | 26,900 |
Brooke, Will | 26,900 |
Johnston, John | 26,900 |
Douglas, Richard | 26,900 |
Total | 729,200 |
Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 January 2020, of 136.00 pence (being the closing share price on the day of the Trading Update).
The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Names | Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard |
2 | Reason for the notification | |
a) | Position/status
| Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director |
b) | Initial notification /Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | MaxCyte, Inc. |
b) | LEI | 54930053YHXULRFCU991 |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a)
| Description of the financial instrument, type of instrument | Grant of Options over Shares of Common Stock |
b) | Identification code | US57777K1060 |
c) | Nature of the transactions |
Grant of Options to PDMRs |
d)
| Price(s) and volume(s) | Doerfler, Doug - 390,200 at an exercise price of 136.00 pence Holtz, Ron - 177,600 at an exercise price of 136.00 pence Thompson, J. Stark - 26,900 at an exercise price of 136.00 pence Mandell, Art - 26,900 at an exercise price of 136.00 pence Erck, Stan - 26,900 at an exercise price of 136.00 pence Brooke, Will - 26,900 at an exercise price of 136.00 pence Johnston, John - 26,900 at an exercise price of 136.00 pence Douglas, Richard - 26,900 at an exercise price of 136.00 pence |
d)
| Aggregated information - Aggregated volume - Price | n/a |
e)
| Date of the transactions | 20 January 2020 |
f) | Place of the transaction | Outside a trading venue |
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers and the potential pre-commercial milestones from these relationships now exceeds $650 million. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit www.maxcyte.com
For further information, please contact:
|